Literature DB >> 2572250

Effects of xamoterol on resting and exercise haemodynamics in patients with chronic heart failure.

S J Virk1, M K Davies.   

Abstract

1. A bicycle exercise test was used to investigate functional capability and haemodynamics in 30 patients with heart failure (13 NYHA Class II, 17 Class III), before and after i.v. xamoterol (Corwin, Carwin, Corwil, Xamtol, ICI 118,587) 0.2 mg kg-1. 2. Resting heart rate fell from 78 to 74 beats min-1 (P less than 0.05) and cardiac index rose from 2.5 to 2.8 l min-1 m-2 (P less than 0.001) after xamoterol. Blood pressure fell slightly, and systemic vascular resistance was reduced. Stroke work index improved and double product decreased. There were no changes in pulmonary artery wedge pressure ejection fraction or plasma noradrenaline concentrations. 3. On exercise, xamoterol produced a considerable reduction in heart rate increase, improved stroke volume and left ventricular stroke index and lowered double product. Exercise duration increased by 10%, but this did not quite achieve statistical significance. 4. These results are consistent with the concept that a beta 1-partial adrenoceptor agonist with the level of intrinsic sympathomimetic activity (43%) of xamoterol provides moderate inotropic support at rest, and protects the heart against overstimulation on exercise, when sympathetic drive is high. 5. Reduction of double product on exercise implies a lowered oxygen demand, which could be of considerable importance in patients with ischaemic heart disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2572250      PMCID: PMC1379872     

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  25 in total

1.  CATECHOLAMINE EXCRETION AND CARDIAC STORES OF NOREPINEPHRINE IN CONGESTIVE HEART FAILURE.

Authors:  C A CHIDSEY; E BRAUNWALD; A G MORROW
Journal:  Am J Med       Date:  1965-09       Impact factor: 4.965

2.  Isoproterenol-induced cardiac hypertrophy: modifications in characteristics of beta-adrenergic receptor, adenylate cyclase, and ventricular contraction.

Authors:  J Tse; J R Powell; C A Baste; R E Priest; J F Kuo
Journal:  Endocrinology       Date:  1979-07       Impact factor: 4.736

3.  Plasma norepinephrine in congestive heart failure.

Authors:  J A Thomas; B H Marks
Journal:  Am J Cardiol       Date:  1978-02       Impact factor: 2.778

4.  Adverse effects of beta-blockade withdrawal in patients with congestive cardiomyopathy.

Authors:  K Swedberg; A Hjalmarson; F Waagstein; I Wallentin
Journal:  Br Heart J       Date:  1980-08

5.  Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure.

Authors:  T B Levine; G S Francis; S R Goldsmith; A B Simon; J N Cohn
Journal:  Am J Cardiol       Date:  1982-05       Impact factor: 2.778

6.  Catecholamine-specific desensitization of adenylate cyclase. Evidence for a multistep process.

Authors:  Y F Su; T K Harden; J P Perkins
Journal:  J Biol Chem       Date:  1980-08-10       Impact factor: 5.157

7.  Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol.

Authors:  W S Colucci; R W Alexander; G H Williams; R E Rude; B L Holman; M A Konstam; J Wynne; G H Mudge; E Braunwald
Journal:  N Engl J Med       Date:  1981-07-23       Impact factor: 91.245

8.  Mechanism of isoprenaline-induced refractoriness of the beta-adrenoceptor--adenylate cyclase system in chick embryo cardiac cells.

Authors:  A Bobik; J H Campbell; V Carson; G R Campbell
Journal:  J Cardiovasc Pharmacol       Date:  1981 May-Jun       Impact factor: 3.105

9.  Beneficial effects of long-term beta-blockade in congestive cardiomyopathy.

Authors:  K Swedberg; A Hjalmarson; F Waagstein; I Wallentin
Journal:  Br Heart J       Date:  1980-08

10.  Catecholamine-induced subsensitivity of adenylate cyclase associated with loss of beta-adrenergic receptor binding sites.

Authors:  C Mukherjee; M G Caron; R J Lefkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  1975-05       Impact factor: 11.205

View more
  3 in total

1.  A comparison of the chronic effects of oral xamoterol and enalapril on blood pressure and renal function in mild to moderate heart failure.

Authors:  M J Jamieson; J Webster; G Fowler; J Rawles; F W Smith; J C Petrie
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

2.  Lack of pharmacodynamic interactions between acute dose flosequinan and xamoterol. A pilot study in healthy subjects.

Authors:  H W Ng; T J Walley; Y Tsao; A M Breckenridge
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 3.  Effects of beta-blockers on neurohormonal activation in patients with congestive heart failure.

Authors:  D Baran; E M Horn; K Hryniewicz; S D Katz
Journal:  Drugs       Date:  2000-11       Impact factor: 11.431

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.